Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020141199 - METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER


Disclaimer The image version (PDF) available on PATENTSCOPE is the official version. This online html version is provided to assist users. Despite the great care taken in its compilation to ensure a precise and accurate representation of the data appearing on the printed document/images, errors and/or omissions cannot be excluded due to the data transmittal, conversion and inherent limitations of the (optional) machine translation processes used. Hyperlinks followed by this symbol , are to external resources that are not controlled by WIPO. WIPO disclaims all liability regarding the above points.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/EP2020/050039 HERMIN1634102MC
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
02 January 2020 03 January 2019
Applicant
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA...
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
a. forming part of the international application as filed:
in the form of an Annex C/ST.25 text file.
on paper or in the form of an image file.
b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
c. furnished subsequent to the international filing date for the purposes of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.
In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.
Additional comments:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
This International Searching Authority found multiple inventions in this international application, as follows:
1. claims: 1-10
Method of treating cancer by a NRP-1 inhibitor
2. claims: 11-16, 21-29
The use of an immune checkpoint inhibitor in combination with a NRP-1 inhibitor to treat cancer. Multi-specific antibodies with at least a NRP-1 and an immune checkpoint binding site and use of said antibody to treat cancer.
3. claim: 17
Method of treating cancer by administering a NRP-1 inhibitor and a cancer vaccine
4. claims: 18-20
A method of predicting a response with immune checkpoint inhibitor in a patient with cancer based on determination of expression levels of NRP-1 and Semaphorin 3A. A method of treating cancer patient with a NRP-1 inhibitor based on low levels of measured NRO-1 and Semaphorin 3A in a tumor sample.
5. claims: 30-36
Population of cells engineered to express a chimeric antigen receptor (CAR) with repressed NRP-1 expression. Method of manufacturing such cells. Method of treating a cancer patients with said cells.
1.
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.
As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.
As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.
No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest
The additional search fees were accompanied by the applicant’s protest and, where applicable, the payment of a protest fee.
The additional search fees were accompanied by the applicant’s protest but the applicable protest fee was not paid within the time limit specified in the invitation.
No protest accompanied the payment of additional search fees.
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     G01N 33/574 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     G01N
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, WPI Data, EMBASE, BIOSIS, INSPEC, COMPENDEX, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
YUAN DING ET AL, "Anti-neuropilin-1 monoclonal antibody suppresses the migration and invasion of human gastric cancer cells via Akt dephosphorylation", EXPERIMENTAL AND THERAPEUTIC MEDICINE,Vol. 16, 30 May 2018 (2018-05-30), page 537-546,
XP055599611
1-3,9,10
relevant for non unity;abstract
page 544, column 2, paragraph 2; figures 2-3,5
(2)
X
GRAZIA GRAZIANI ET AL, "Neuropilin-1 as Therapeutic Target for Malignant Melanoma", FRONTIERS IN ONCOLOGY,Vol. 5, 03 June 2015 (2015-06-03), page 1-9,
XP055385140
1-3,7-10
Relevant for non unity
abstract
page 3, left column, paragraph 5-page 4, right column, paragraph 1
(3)
X
CHANG LIU ET AL, "P679 Neuropilin-1 is a T cell memory checkpoint limiting long-term tumor immunity", JOURNAL FOR IMMUNOTHERAPY OF CANCER,Vol. 6, No. Suppl 1, 06 November 2018 (2018-11-06), page 361,
XP055586720
1,8-10
abstract
(4)
Y
WO 2007056470 A2 (GENENTECH INC [US]; WATTS RYAN J [US]; WU YAN [US]) 18 May 2007 (2007-05-18)
4-6
Antibody YW64.3;claims 1,4,6-10, 21-23; sequences 3-4, 123-128
(5)
Y
LIANG W C ET AL, "Function Blocking Antibodies to Neuropilin-1 Generated from a Designed Human Synthetic Antibody Phage Library", 23 February 2007 (2007-02-23), Vol. 366, No. 3, page 815-829,
XP026268831
[retrieved on  2007-02-01]
4-6
figure 3a
(6)
X
CHUCKRAN C ET AL, "Neuropilin-1 stabilizes human Tregs in cancer patients leading to more potent suppressive function", EMBASE01 November 2018 (2018-11-01), Database accession no. EMB-627524635
Retrieved from the Internet:
URL:ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL
XP002793958
11-13
abstract
& CHUCKRAN C ET AL, "Neuropilin-1 stabilizes human Tregs in cancer patients leading to more potent suppressive function",  JOURNAL FOR IMMUNOTHERAPY OF CANCER 20181101 BIOMED CENTRAL LTD. NLD,Vol. 6, No. Supplement 1, 01 November 2018 (2018-11-01),
(7)
X
WO 2014058915 A2 (ST JUDE CHILDRENS RES HOSPITAL [US]) 17 April 2014 (2014-04-17)
11-13,16,17,21,22,29
page 1, line 17 - line 19
page 23, line 30 - page 24, line 2
(8)
A
HODI FRANK STEPHEN ET AL, "Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL,Vol. 19, No. 11, 22 October 2018 (2018-10-22), page 1480-1492,
XP085521849
14,15
abstract
(9)
A
HAMID OMID ET AL, "Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006", 11 September 2018 (2018-09-11), Vol. 119, No. 6, page 670-674,
XP036881276
[retrieved on  2018-09-11]
14,15
abstract
(10)
A
US 2018333503 A1 (RUIZ SOTO RODRIGO R [US]) 22 November 2018 (2018-11-22)
25,27
claim 13
(11)
A
WO 2018222711 A2 (SQUIBB BRISTOL MYERS CO [US]) 06 December 2018 (2018-12-06)
26,28
claims 1-3,12,13; sequences 18,19
(12)
A
WO 2017055404 A1 (F HOFFMANN-LA ROCHE AG [CH]; HOFFMANN-LA ROCHE INC [US]) 06 April 2017 (2017-04-06)
23-28
claims 1-19, 27,30
(13)
X,P
MARINE LECLERC ET AL, "Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1", NATURE COMMUNICATIONS,Vol. 10, No. 1, 26 July 2019 (2019-07-26), page 1-14,
XP055616283
1-36
the whole document
(14)
X
LIU C ET AL, "Neuropilin-1 is a T cell memory checkpoint limiting long-term tumor immunity", EMBASE01 November 2018 (2018-11-01), Database accession no. EMB-627524310
Retrieved from the Internet:
URL:ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL
XP002793959
17
abstract
& LIU C ET AL, "Neuropilin-1 is a T cell memory checkpoint limiting long-term tumor immunity",  JOURNAL FOR IMMUNOTHERAPY OF CANCER 20181101 BIOMED CENTRAL LTD. NLD,Vol. 6, No. Supplement 1, 01 November 2018 (2018-11-01),
XP002793959
(15)
A
ZAPPASODI ROBERTA ET AL, "Strategies for Predicting Response to Checkpoint Inhibitors", 29 August 2018 (2018-08-29), Vol. 13, No. 5, page 383-395,
XP036722597
[retrieved on  2018-08-29]
18-20
table 3
(16)
X
WO 2017075451 A1 (BROAD INST INC [US]; MASSACHUSETTS INST TECHNOLOGY [US] ET AL.) 04 May 2017 (2017-05-04)
30,31,36
Y
paragraphs [0126], [0808]; claims 1-6,22a,23
33-35
(17)
Y
QI ZHANG ET AL, "CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside", ONCOIMMUNOLOGY,Vol. 5, No. 12, 28 October 2016 (2016-10-28), page e1251539,
XP055617178
33-35
figure 1; table 2
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2007056470 A2
18 May 2007
AU 2006311590 A1
BR PI0619688 A2
CA 2629028 A1
CA 2892180 A1
CN 101326196 A
CN 102304184 A
CR 10017 A
CR 20140518 A
EC SP088508 A
EP 1951758 A2
EP 2570434 A2
IL 190960 A
IL 222922 A
JP 5197376 B2
JP 2009514972 A
JP 2011256183 A
KR 20080068105 A
MA 29975 B1
MY 154904 A
NZ 567514 A
NZ 593289 A
SG 173408 A1
UA 96139 C2
UA 98585 C2
US 2008213268 A1
US 2011256146 A1
US 2012245330 A1
US 2013115214 A1
US 2016304613 A1
WO 2007056470 A2
ZA 200803811 B
ZA 200903718 B
18 May 2007
11 October 2011
18 May 2007
18 May 2007
17 December 2008
04 January 2012
06 November 2008
09 January 2015
30 July 2008
06 August 2008
20 March 2013
29 January 2015
30 July 2015
15 May 2013
09 April 2009
22 December 2011
22 July 2008
03 November 2008
28 August 2015
26 August 2011
21 December 2012
29 August 2011
10 October 2011
25 May 2012
04 September 2008
20 October 2011
27 September 2012
09 May 2013
20 October 2016
18 May 2007
26 August 2009
30 March 2011
WO 2014058915 A2
17 April 2014
AU 2013329372 A1
AU 2018228501 A1
CA 2886120 A1
EP 2903692 A2
JP 2015533127 A
JP 2018172436 A
US 2015266959 A1
US 2017137524 A1
US 2020010552 A1
WO 2014058915 A2
02 April 2015
27 September 2018
17 April 2014
12 August 2015
19 November 2015
08 November 2018
24 September 2015
18 May 2017
09 January 2020
17 April 2014
US 2018333503 A1
22 November 2018
AU 2018269173 A1
CA 3063893 A1
CN 110799535 A
EP 3625262 A1
KR 20200006546 A
TW 201900221 A
US 2018333503 A1
WO 2018213260 A1
28 November 2019
22 November 2018
14 February 2020
25 March 2020
20 January 2020
01 January 2019
22 November 2018
22 November 2018
WO 2018222711 A2
06 December 2018
AU 2018277559 A1
BR 112019018759 A2
CA 3060989 A1
CN 110691795 A
EP 3630842 A2
KR 20200010500 A
WO 2018222711 A2
17 October 2019
05 May 2020
06 December 2018
14 January 2020
08 April 2020
30 January 2020
06 December 2018
WO 2017055404 A1
06 April 2017
AU 2016329126 A1
BR 112018001530 A2
CA 2992853 A1
CL 2018000502 A1
CN 108137699 A
CO 2018000886 A2
CR 20180161 A
EP 3356411 A1
JP 6622392 B2
JP 2018537950 A
JP 2020058353 A
KR 20180042417 A
PE 7732018 A1
PH 12018500635 A1
TW 201718660 A
US 2017114135 A1
US 2019322748 A1
WO 2017055404 A1
15 February 2018
06 November 2018
06 April 2017
27 July 2018
08 June 2018
19 April 2018
25 May 2018
08 August 2018
18 December 2019
27 December 2018
16 April 2020
25 April 2018
07 May 2018
24 September 2018
01 June 2017
27 April 2017
24 October 2019
06 April 2017
WO 2017075451 A1
04 May 2017
US 2019106678 A1
WO 2017075451 A1
11 April 2019
04 May 2017
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
17 March 2020
Date of mailing of the international search report:
08 June 2020
Authorized officer:
van der Kooij, M
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E